Asahi Kasei Starts Pediatric Cresemba Trial
Asahi Kasei Therapeutics has started a Phase 2 trial of Basilea's Cresemba (Isavuconazol) in children at risk of deep-seated mycoses.
PipDig Newsroom ·
Read briefingThe following Forex news reports are the latest developments of the Forex market. The news reports are updated frequently and include all the events that affect the foreign exchange trading industry.
Asahi Kasei Therapeutics has started a Phase 2 trial of Basilea's Cresemba (Isavuconazol) in children at risk of deep-seated mycoses.
PipDig Newsroom ·
Read briefingAsahi Kasei Therapeutics Corp. began a phase 2 study of Cresemba, an isavuconazole antifungal, in pediatric patients at risk of deep mycoses in Japan.
Read briefingOTC Markets Group signed a market data deal with CITIC Securities Brokerage (HK), extending U.S. quote access to its Hong Kong platform.
Read briefingNBPE bought back 50,000 Class A shares at £14.70 on 11 September 2026, cutting outstanding shares to 38,891,702.
Read briefingSretaw Group Treasury Operations disclosed a 6.532% combined stake in Irish Continental Group plc, crossing the 6% voting-rights threshold on 9th September 2026.
Read briefingFederal bank regulatory agencies requested comment on proposed third-party risk management guidance on September 11, 2026.
Read briefingThe European Commission has put forward proposals to the Council for signature and conclusion of the EU-India free trade agreement.
Read briefingSEC, FDIC, CFTC, Fed and Bank of England met Sept. 3, 2026 to review joint work on CCP resolution planning.
Read briefingThe EU's ETS reform now covers all private jets, while 90% of member state funds bypass industrial decarbonisation.
Read briefing